Notwithstanding these limitations, recent studies demonstrate an incidence of approximately 0.2% of cardiomyocytes with apoptosis at the time of cardiac transplantation. 3 4 Using this incidence, Feuerstein and colleagues calculated that approximately 25% of total muscle mass would be lost on an annual basis. 5 This amount of cardiomyocyte loss may be feasible in patients with preterminal heart failure, but incompatible with the life expectancy of patients with chronic stable heart failure. 6 We therefore hypothesise that the number of cardiomyocytes undergoing apoptosis in stable heart failure is considerably lower and of lesser significance than that reported in advanced pretransplant heart failure.
Anti-apoptotic eVects of current heart failure treatment With the improved outcome in patients with stable cardiomyopathy, 7 a question arising is whether the survival promoting drugs used in the treatment of heart failure, in eVect, retard the onset of apoptosis? To explore this, the concept of susceptibility to apoptosis as described by Depre and Taegtmeyer is useful to consider.
8 These investigators described how a drift from cardiac contractile and energetic homeostasis confers greater vulnerability of the failing heart to apoptotic signals such as ischaemia, pressure-overload, tumour necrosis factor (TNF ), reactive oxygen species, and excess nitric oxide. In this regard angiotensin converting enzyme inhibitors and adrenergic antagonists have been shown, in experimental conditions, to promote resistance to apoptotic signals in the heart. 9 10 These cell survival promoting eVects may explain part of the protective mechanism of these agents in heart failure.
Pentoxifylline as an anti-apoptotic agent?
Accordingly, a study in this issue by Skudicky and colleagues is intriguing. 11 They demonstrate a significant reduction in two apoptotic mediators (TNF and Fas) and an improvement in contractile function in a group of patients with idiopathic cardiomyopathy treated with pentoxifylline. In this six month study, the matched control group had no deterioration in their cardiac contractile function. These data suggest that pentoxifylline may, in part, restore the contractile energetic homeostatic balance in the heart. Contractile function may improve either through the reduction in TNF mediated cardiodepression, 12 and/or via increased intracellular cyclic adenosine monophosphate through phosphodiesterase inhibition by pentoxifylline in the treated group. 13 However, based on the fact that there is a low prevalence of apoptosis in stable heart failure, and that attenuating apoptosis is unlikely to improve contractile function, the positive eVects on contractile function of pentoxifylline are probably not caused by an anti-apoptotic eVect despite the correlation with the plasma concentrations of Fas. Moreover, if the contractile improvement is caused by phosphodiesterase inhibition, this eVect may be, in the longer term, detrimental to mortality as has been shown with other phosphodiesterase inhibitors. However, as TNF depresses contractile function in the stable heart failure patient and may augment apoptosis in the preterminal patient, the current studies on the direct eVect of TNF inhibition in heart failure are eagerly awaited.
14 Skeletal muscle apoptosis in heart failure A second article in this issue by Vescove and colleagues elegantly describes an increased incidence of apoptosis in skeletal muscles of subjects with heart failure. 15 Here the incidence of apoptosis is inversely correlated with peak VO 2 and is postulated to be an important process in limited exercise capacity in these subjects. Moreover, the authors postulate that this apoptosis may be triggered by circulating TNF . As the patient numbers are small in this study, it would be of interest to evaluate whether heart failure subjects treated with TNF inhibitors demonstrate an improvement in peak VO 2 .
Direct anti-apoptotic treatment in the management of heart failure? An important question is whether directly blocking the apoptotic programme is a feasible strategy in heart failure treatment. The hypothetical risks of directly blocking apoptosis include an increased risk of neoplastic and autoimmune diseases. 16 Thus, it is unlikely to be of overall benefit in the treatment of chronic diseases such as heart failure. Also no data exist which can determine when and if apoptosis begins to play an important role in deterioration of contractile function in subjects with chronic stable heart failure. In contrast, data are emerging which suggest that the heart can exhibit pronounced plasticity and can show improved contractile function in end stage heart failure-for example, when the heart is unloaded using the left ventricular assist device. 17 Finally, additional data which support an ability to sustain life, even with a very poor left ventricular contractile function, has been shown in the Canadian implantable defibrillator study. 18 These last two studies, albeit in small numbers of patients, contradict the concept that apoptosis may be a central component to the heart failure syndrome, at least in the absence of ongoing pathologic insults.
In conclusion, we believe that the current literature supports the presence of apoptosis during heart failure. However, the process itself is probably most prevalent in the premorbid heart and of limited clinical significance in the progression of heart failure in the absence of ongoing pathological insults. Furthermore, because of the theoretical risks of blocking apoptosis directly, direct anti-apoptotic agents are unlikely candidates for heart failure treatment in the near future. Strategies to diminish ongoing insult to the heart, and treatments to maintain contractile energetic homeostasis, with the resultant elevation of the apoptotic threshold, would probably have greater merit in our continuous eVorts to improve the lives of patients with heart failure. 
DAVID MARSHALL MICHAEL N SACK

